Generics Bulletin: unrivaled news and analysis of the global generics, biosimilars, and value-added medicines industries

Home / Our Products / Commercial Products / Generics Bulletin

Generics Bulletin

Unrivaled news and analysis of the global generic, biosimilars, and value-added medicines industries.

Unrivaled news & analysis of the global generics, biosimilars, and value-added medicines industries

A trusted industry source since 2003, Citeline’s Generics Bulletin delivers in-depth news and analysis on the latest regulatory, legal, market, and commercial developments in the global generics, biosimilars, and value-added medicines industries.

There’s nothing generic about it; our broad network of global expert analysts and journalists covers it in depth, from competitive intel and M&As to new product launches, manufacturing updates, marketing challenges, advertising strategies and more.

At Rosemont, we very much value the insights and news features shared via Generics Bulletin. For an organisation of our size and stage of evolution, having access to such a contemporary resource is a notable element of our business intelligence capability. We also appreciate their customer engagement; seeking to work with us collaboratively.

Howard Taylor, CEO, Rosemont Pharmaceuticals

I've been reading Generics Bulletin for over a decade now and it is really of great help to understand the latest news related to generics and biosimilars, including Licensing and M&A deals as well as new Authorities regulations.

Alex Falgas, Global SVP - BD Portfolio & Strategy, Corporate Europe & MENA , Accord Healthcare

Generics Bulletin is, quite simply, the trade journal of the off-patent medicines industry: the number one source of reliable, balanced information about the people and companies who provide 80% of the world’s medicines at a fraction of the cost. Keep up the good work!

Steffen Kurzawa, Global Head Corporate Affairs, Sandoz

New medicine product news and analysis are included in Citeline's Generics Bulletin offerings.

In-depth news and analysis

How it helps

A comprehensive and dependable information source aimed at ensuring industry leaders can stay on top of the latest regulatory, legal, market and commercial developments to anticipate potential threats and identify new opportunities.

How it works

We offer a broad network of global expert analysts and journalists who you can rely on to provide valuable news and insight by tracking market events and their impacts from around the globe. We’re here to help you understand the potential impact of developments and trends on your business. Plus, you can access exclusive interviews with key opinion leaders and market movers for insider knowledge that will help you stay ahead of the competition.

Analysis and opinion covers key topic areas such as:

regulatory and compliance changes
legal and legislations advances
competitive developments
merger and acquisition activities
new product launches

What's included

Ask-the-Analyst™ Service

We offer a direct connection to the industry-leading experts who write our content, so that they can answer your questions on the news stories, topics and insights you read about.

A powerful online platform

Access unparalleled news, expert coverage and analysis from any internet-connected device and customize the content to stay on top of the news and topics you care about.

In-depth content coverage

We cover generics, biosimilars and value-added medicines from key regions around the world, with breaking news from industry-leading experts across each sector.

Global analysts and journalists

Access impartial opinions and news updates from our global team of analysts and journalists who track market events to understand the potential impact of developments to your business.

Our experts

Citeline’s award-winning publications provide in-depth coverage of the pharmaceutical industry, thanks to 65 in-house journalists who tackle the tough issues with precision, persistence and passion.

We provide comprehensive industry news, on areas ranging from pharmaceutical regulation and policy to generics and the medtech industry.

Our 300+ analysts are trusted advisers to a broad spectrum of the industry, including biopharma, biotechs, financial and professional services, CDMOs and CROs.